EPRX
Eupraxia Pharmaceuticals Inc

149
Mkt Cap
$443.17M
Volume
25,633.00
52W High
$8.89
52W Low
$2.68
PE Ratio
-10.07
EPRX Fundamentals
Price
$8.83
Prev Close
$8.75
Open
$8.65
50D MA
$6.77
Beta
0.50
Avg. Volume
136,725.45
EPS (Annual)
-$0.7516
P/B
7.59
Loading...
Loading...
News
all
press releases
Cantor Fitzgerald Raises Eupraxia Pharmaceuticals (NASDAQ:EPRX) Price Target to $19.00
Cantor Fitzgerald upped their price target on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an "overweight" rating in a research report on Thursday...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Average Rating of "Buy" from Analysts
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the seven analysts that are covering the stock, Marketbeat.com reports. One...
MarketBeat·5d ago
News Placeholder
Short Interest in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Grows By 138.8%
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) was the target of a large increase in short interest in December. As of December 31st, there was short interest totaling 1,311,773...
MarketBeat·6d ago
News Placeholder
Eupraxia Trial Data Shows Lasting Tissue Healing In Patients With Inflamed Esophagus
Eupraxia Pharmaceuticals reported new trial data showing EP-104GI improved esophagus tissue health and maintained remission in EoE patients, with no serious safety issues reported.read more...
Benzinga·12d ago
News Placeholder
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Up 30.1% in December
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) saw a large increase in short interest in December. As of December 15th, there was short interest totaling 549,299 shares, an increase of...
MarketBeat·21d ago
News Placeholder
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Consensus Rating of "Buy" by Brokerages
Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) have been assigned an average recommendation of "Buy" from the seven ratings firms that are covering the firm, MarketBeat...
MarketBeat·1mo ago
News Placeholder
FY2025 Earnings Estimate for EPRX Issued By Lifesci Capital
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) - Equities researchers at Lifesci Capital issued their FY2025 earnings per share (EPS) estimates for shares of Eupraxia Pharmaceuticals in a...
MarketBeat·1mo ago
News Placeholder
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen raised Eupraxia Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·1mo ago
News Placeholder
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded to "Strong-Buy" at Lifesci Capital
Lifesci Capital raised shares of Eupraxia Pharmaceuticals to a "strong-buy" rating in a research note on Thursday...
MarketBeat·1mo ago
News Placeholder
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of "Moderate Buy" by Brokerages
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six research firms that are currently covering the firm...
MarketBeat·2mo ago
<
1
2
...
>

Latest EPRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.